On October 29, 2026, China’s commerce ministry condemned a United States decision to add three Chinese medical equipment manufacturers to the Uyghur Forced Labor Prevention Act Entity List. The move blocks goods from MGI Tech, BGI Genomics, and BGI Group from entering the U.S. market unless exporters prove they are free from forced labor.
The escalation marks a sharp turn in bilateral trade tensions. It arrives despite prior high-level diplomatic engagements aimed at stabilizing relations between Beijing and Washington.
Targeting Medical Giants and Supply Chains
The U.S. Customs and Border Protection agency received instructions to halt shipments from the newly targeted firms. According to Reuters reporting, Washington alleges that MGI Tech Co Ltd, BGI Genomics Co Ltd, and Shenzhen BGI Technology Co Ltd—widely known as the BGI Group—use or facilitate the forced labor of Uyghurs and other minorities. The restrictions also target companies sourcing materials from the Xinjiang Uyghur Autonomous Region.
For exporters named on the Entity List, the regulatory hurdle is absolute. Goods face an automatic presumption of forced labor unless companies can definitively rebut that claim through exhaustive supply chain audits.
The targeted firms have pushed back against the allegations. MGI Tech issued a statement rejecting the U.S. claims, maintaining that the company operates with zero tolerance for forced labor. BGI Genomics and its parent, the BGI Group, issued similar denials, stating they do not engage in any form of forced labor.
Diplomatic Friction and Retaliatory Precedents
Beijing wasted little time condemning the enforcement action. The Chinese commerce ministry stated that adding these enterprises to the entity list directly contradicts the consensus reached by the two nations’ heads of state. Beijing demanded that Washington immediately cease what it termed political manipulation, smear campaigns, and the unreasonable suppression of Chinese enterprises, adding that Beijing will take necessary steps to safeguard its national interests.
This latest economic maneuver follows a tit-for-tat regulatory environment established over recent years. In early 2025, Beijing placed rival U.S. medical equipment maker Illumina on its own “unreliable entity” list in a retaliatory trade measure.
International scrutiny over labor practices in the region remains a central point of contention. A group of United Nations experts reported in January that a persistent pattern of alleged forced labor affects Uyghur, Kazakh, and Kyrgyz minority groups, alongside Tibetans, across Xinjiang and multiple other provinces in China. Beijing has consistently rejected these allegations as groundless.
| Company / Entity | Headquarters / Origin | Action Taken | Timing |
|---|---|---|---|
| MGI Tech Co Ltd | China | Added to U.S. Uyghur Forced Labor Prevention Act Entity List | Late October 2026 |
| BGI Genomics Co Ltd | China | Added to U.S. Uyghur Forced Labor Prevention Act Entity List | Late October 2026 |
| BGI Group (Shenzhen BGI Technology) | China | Added to U.S. Uyghur Forced Labor Prevention Act Entity List | Late October 2026 |
| Illumina | United States | Placed on China’s “unreliable entity” list | Early 2025 |
As customs authorities begin enforcing the import restrictions, global supply chains in the biotechnology and medical device sectors face renewed friction. Neither government has indicated an immediate willingness to de-escalate the trade dispute.
